|Articles|September 10, 2014

PRA Health Sciences Files for Initial Public Offering

PRA Health Sciences announced that it has filed a registration statement with the US Securities and Exchange Commission

PRA Health Sciences announced that it has filed a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public offering (“IPO”) of shares of its common stock by PRA Health Sciences. The number of shares to be offered and the price range has not yet been determined.

Read the full release here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

PRA Health Sciences Files for Initial Public Offering

Related Content

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

Trending on Applied Clinical Trials Online

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

ACT Brief: Multimodal AI Systems Architecture, Trust-Based Trial Recruitment, and Big Pharma AI Transformation